Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 65 to 90

Timing nalbuphine for pain relief and blood pressure control during knee replacement in older adults

Official title: Effects of Different Administration Timings of Nalbuphine on Hemodynamics and Postoperative Analgesia in Elderly Patients Undergoing Total Knee Arthroplasty

Run by Qianfoshan Hospital · NCT07271849 · Data updated 2026-11-12

We will test whether giving nalbuphine at different times during knee replacement helps control pain and stabilize blood pressure in people 65 and older.

More Hemodynamics trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages65 Years to 90 Years
SexAll
Enrollment162 (estimated)
SponsorQianfoshan Hospital
Academic / other
Locations1 site (Jinan, Shandong)
StatusRecruiting
StartedOctober 28, 2025
Main results expectedOctober 1, 2026
Study endsOctober 31, 2026
Registry record updatedDecember 9, 2025
Trial IDNCT07271849 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 65 or older undergoing unilateral total knee arthroplasty under general anesthesia with BMI 18–30, ASA I–III, normal mental status, and no contraindications to nalbuphine.

Probably not a fit

Patients with uncontrolled hypertension, severe respiratory disease, significant liver or kidney dysfunction, or who fall outside the specified age or BMI ranges are unlikely to be eligible or benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 interventional trial compares three approaches to perioperative nalbuphine use in elderly patients undergoing unilateral total knee arthroplasty under general anesthesia: nalbuphine at induction, nalbuphine after cement implantation, or standard care without nalbuphine. Investigators will monitor intraoperative hemodynamics, proxies for cerebral perfusion, postoperative pain scores, total opioid consumption, and opioid-related side effects such as nausea and vomiting. Eligible participants are adults aged 65 or older with BMI 18–30 and ASA physical status I–III who consent and meet laboratory criteria. The study aims to determine whether the timing of nalbuphine administration improves hemodynamic stability and reduces postoperative pain and opioid needs.

Why it matters

Potential benefit: If successful, timing nalbuphine appropriately could reduce pain and opioid use while improving blood pressure stability and cerebral perfusion during and after knee replacement in older patients.

How similar studies have gone: Prior clinical work shows nalbuphine provides effective postoperative analgesia with fewer mu-opioid side effects than morphine, but using specific timing to improve intraoperative hemodynamics in elderly TKA patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All study participants voluntarily enrolled in the trial and provided written informed consent after being fully informed of the trial's purpose and significance
* Participants underwent unilateral total knee arthroplasty under general anesthesia
* Elderly participants (age ≥ 65 years), regardless of gender
* Body mass index (BMI) ranging from 18 kg/m² to 30 kg/m²
* Absence of psychiatric disorders, normal consciousness, and ability to communicate effectively
* American Society of Anesthesiologists (ASA) physical status classification I-III;
* No contraindications to the study medications

Exclusion Criteria:

* Study participants with uncontrolled or untreated hypertension (resting systolic/diastolic blood pressure \>180/100 mmHg)
* Individuals with severe respiratory diseases
* Subjects with abnormal liver or renal function (ALT and/or AST \>2.5 times the upper limit of normal, total bilirubin \>1.5 times the upper limit of normal, serum creatinine \>1.5 times the upper limit of normal)
* Individuals with a history of drug abuse, illicit drug use, or alcohol abuse, where alcohol abuse is defined as an average daily alcohol intake exceeding 2 units (1 unit = 360 mL of beer, 45 mL of 40% alcohol by volume spirits, or 150 mL of wine)

Where it's running

  • Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University,
    Jinan, Shandong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.